Overview

GMP (Good Manufacturing Practice) and GSP (Good Supply Practice) are the two core quality-management norms for drug manufacturing and distribution in China, and the primary legal basis for routine and unannounced inspections by the drug authority.

GMP/GSP compliance is not merely a technical matter — it is a legal one. Consequences range from warnings, fines and suspension to licence revocation and criminal liability (counterfeit / substandard drug offences). Since the GMP certification permit was abolished, post-approval supervision has tightened and unannounced inspections have become more frequent and forceful. Companies need a systematic, continuous compliance programme.

GMP compliance — manufacturing quality

Legal framework

  • Drug Administration Law, Art. 42–46 — GMP principles and liability
  • Measures for the Supervision of Drug Manufacturing — licences and inspection
  • GMP (2010 revision) — technical requirements, with 13 appendices (sterile products, biologics, blood products, TCM, APIs, etc.)
  • ICH Q7 / Q10 and other international standards as reflected in Chinese GMP

Important change: since the 2019 Drug Administration Law revision, GMP certification has been abolished in favour of continuous GMP conformity inspection. No more five-year certificates — the authority assesses conformity through routine, unannounced and targeted inspections. Companies can no longer "get the certificate and forget it"; they must maintain GMP continuously.

Core GMP compliance areas

  • Quality management system: a pharmaceutical quality system (PQS) covering quality policy, objectives and quality risk management, keeping every step from raw material to batch release under control.
  • Personnel and organisation: qualification and duties of key personnel, including the qualified person (QP) whose independent release authority is legally protected from interference by management.
  • Facilities: cleanroom grades (A/B/C/D), temperature/humidity control, pressure cascades, and segregated facilities for high-potency, sensitising or β-lactam products.
  • Equipment and process validation: DQ/IQ/OQ/PQ, and the three-stage process validation of design, confirmation and continued verification.
  • Materials and suppliers: specifications for raw materials and packaging, supplier audits (including overseas), and validation/registration for supplier changes.
  • QC laboratory: instrument calibration, reference standards, OOS/OOT investigations, stability studies and data integrity — the area with the most inspection findings.
  • Documentation: batch records, test records and SOPs — legible, unalterable, with signed and dated corrections.

Data integrity — the highest-risk area

Data integrity is where Chinese (and FDA/EMA) inspections find the most and the most severely punished violations. The core principle is ALCOA+:

  • Attributable — every record traceable to the person who generated it
  • Legible — permanently preserved and readable
  • Contemporaneous — recorded at the time of the activity
  • Original — original records preserved, not substituted
  • Accurate — faithfully reflecting operations
  • Plus Complete, Consistent, Enduring and Available

Typical violations include "testing into compliance" (retesting until a passing result), selective use of data, overwriting or deleting original data, backdating and disabling audit trails.

Legal warning: data-integrity fraud not only fails GMP inspection and draws administrative penalties — in serious cases it can constitute the crime of providing false supporting documents (Criminal Law Art. 229) or the counterfeit/substandard drug offences (Art. 141/142), exposing management and responsible individuals to criminal prosecution. GMP compliance is a legal risk-management matter for the boardroom, not a technician's chore.

Unannounced inspection response

Unannounced inspections are among the most effective current enforcement tools. They may be triggered by complaints, failed sampling, adverse-reaction signals, media exposure or random selection.

  • Pre-inspection preventive audit: simulate the inspection to identify weaknesses and remedy them.
  • During the inspection: clarify the inspectors' authority, protect the company's rights, and assess findings in real time.
  • After the inspection: legal analysis of deficiencies, review of remediation, and drafting the reply.
  • Serious-defect defence: administrative reconsideration or litigation against suspension, recall or licence revocation.

GSP compliance — distribution quality

Legal framework

  • Drug Administration Law, Art. 52–59 — distribution principles
  • Measures for the Supervision of Drug Distribution
  • GSP — wholesale, retail chains and retail stores
  • Measures for the Supervision of Online Drug Sales

Core GSP areas

  • Procurement: supplier qualification, first-time product review and contract compliance.
  • Receiving and storage: batch-by-batch inspection, storage-condition classification (room temperature / cool / cold / frozen) and automated temperature monitoring.
  • Sales and transport: selling only to licensed hospitals and distributors; cold-chain temperature control and records.
  • Voucher management: matching and retaining purchase invoices, sales invoices and accompanying documents.

The "two-invoice" policy

Introduced in 2016, the two-invoice policy requires one invoice from manufacturer to distributor and one from distributor to hospital, compressing the distribution chain. Key compliance points:

  • First invoice consistency with the awarded (VBP) price
  • Second invoice not exceeding permitted mark-up (public hospitals sell at zero mark-up)
  • Exceptions — domestic general agents for imported drugs and MAH-delegated sales
  • Invoice / goods / accompanying-document consistency to prevent "ticket running" and nominal affiliation

Drug traceability

Under Drug Administration Law Art. 12, MAHs, manufacturers, distributors and users must establish a traceability system and provide traceability information.

  • Traceability codes: every minimum packaging unit carries a code — "one product, one code".
  • Platforms: companies may build their own or join a third-party platform.
  • Interoperability: upstream and downstream traceability information must interconnect.
  • Liability: failure to implement traceability leads to correction orders, warnings and fines of CNY 100,000–500,000 for non-compliance.

Cold-chain management

Cold-chain products (vaccines, blood products, biologics, some antibiotics, stored at 2–8°C or lower) are a top GMP/GSP priority.

  • Cold-chain equipment validation and routine monitoring
  • Temperature-excursion handling procedures during transport
  • Quality risk assessment after a cold-chain break (release or disposal)
  • Full electronic traceability and temperature records for vaccines

Typical penalties

ViolationLegal basisTypical penalty
Serious GMP defect (data-integrity fraud, unauthorised process change, sterile-assurance failure)Drug Administration Law Art. 126Fines of CNY 500,000–2,000,000; in serious cases, suspension of production or revocation of the approval document and licence; responsible persons fined CNY 20,000–200,000 and barred from the industry for 10 years to life.
Manufacturing substandard drugsArt. 117Fines of 10–20× the goods' value (floor of CNY 100,000); revocation of licence in serious cases; responsible persons fined 30%–3× their income and barred 10 years to life.
Manufacturing counterfeit drugsArt. 116 / Criminal Law Art. 141Fines of 15–30× the goods' value; licence revocation; criminal prosecution with a possible death penalty.
Failure to establish traceabilityArt. 127Warning, then fines of CNY 100,000–500,000.
GSP violation (improper storage, non-compliant counterparties)Art. 126Same scale as serious GMP defects.